2 Information about upadacitinib

Marketing authorisation indication

2.1 Upadacitinib (Rinvoq, AbbVie) is indicated 'for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for upadacitinib.


2.3 The list price per 28‑tablet pack of upadacitinib is £805.56 for 15‑mg tablets, £1,281.54 for 30‑mg tablets and £2,087.10 for 45-mg tablets (excluding VAT; BNF online, accessed May 2023).

2.4 The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.